Avanos Medical, Inc.
AVNS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $687,800 | $673,300 | $684,100 | $744,600 |
| % Growth | 2.2% | -1.6% | -8.1% | – |
| Cost of Goods Sold | $306,500 | $293,600 | $289,900 | $364,700 |
| Gross Profit | $381,300 | $379,700 | $394,200 | $379,900 |
| % Margin | 55.4% | 56.4% | 57.6% | 51% |
| R&D Expenses | $26,200 | $27,200 | $30,600 | $32,300 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $315,100 | $287,500 | $323,100 | $260,800 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $341,300 | $314,700 | $352,300 | $293,100 |
| Operating Income | $40,000 | $65,000 | $41,900 | $86,800 |
| % Margin | 5.8% | 9.7% | 6.1% | 11.7% |
| Other Income/Exp. Net | -$443,300 | -$72,900 | -$15,200 | -$79,500 |
| Pre-Tax Income | -$403,300 | -$7,900 | $26,700 | $7,300 |
| Tax Expense | -$17,000 | $2,000 | $5,200 | $1,000 |
| Net Income | -$392,100 | -$61,800 | $50,500 | $6,300 |
| % Margin | -57% | -9.2% | 7.4% | 0.8% |
| EPS | -8.53 | -1.33 | 1.08 | 0.13 |
| % Growth | -541.4% | -223.1% | 730.8% | – |
| EPS Diluted | -8.53 | -1.33 | 1.07 | 0.13 |
| Weighted Avg Shares Out | 46,000 | 46,600 | 46,900 | 48,100 |
| Weighted Avg Shares Out Dil | 46,000 | 46,600 | 47,300 | 48,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,100 | $2,900 | $1,200 | $200 |
| Interest Expense | $12,200 | $15,000 | $10,000 | $3,300 |
| Depreciation & Amortization | $45,500 | $43,500 | $41,100 | $38,300 |
| EBITDA | -$345,600 | $50,600 | $77,800 | $48,900 |
| % Margin | -50.2% | 7.5% | 11.4% | 6.6% |